The nonprofit Center for Therapeutic Genetics (CTG) will have a small physical space at the Broad Institute of MIT and ...

San Diego-based Axiom Biosciences intends to go public via a listing on the Hong Kong Stock Exchange (HKEX) followed by a ...

Bristol Myers Squibb has touted its strengthened collaboration with Nvidia as aiming to build the “most powerful AI factory ...

Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in ...

Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. | Scribe Therapeutics has put its IPO plans down on ...

A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on ...

Every year, the BIO International Convention brings together more than 20,000 leaders from across the global life sciences ...

As biomanufacturing investment accelerates, workforce readiness has emerged as a critical bottleneck. | Ohio’s $30M training ...

For emerging biotech companies, the race to IND is no longer defined by speed alone. | Lonza explains why early de-risking ...

After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum. The ...

Abbott has been struck by a cyberattack that targeted the medtech giant’s cancer diagnostics and LabCentral businesses. Abbott revealed the first attack on July 16 when it said in a statement that its ...

Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. | Another biotech is squeezing ...